Redeye lowers estimate and fair value for Surgical Science - Marketscreener.com
| SUS Stock | SEK 148.50 2.40 1.64% |
Slightly above 55% of Surgical Science's private investors are presently thinking to get in. The analysis of current outlook of investing in Surgical Science Sweden suggests that some traders are interested regarding Surgical Science's prospects. Surgical Science's investing sentiment can be driven by a variety of factors including economic data, Surgical Science's earnings reports, geopolitical events, and overall market trends.
Surgical |
Redeye lowers estimate and fair value for Surgical Science Marketscreener.com
Read at news.google.com
 |
Surgical Science Fundamental Analysis
We analyze Surgical Science's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Surgical Science using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Surgical Science based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
EBITDA
EBITDA Comparative Analysis
Surgical Science is currently under evaluation in ebitda category among its peers. EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Surgical Science Sweden Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Surgical Science stock to make a market-neutral strategy. Peer analysis of Surgical Science could also be used in its relative valuation, which is a method of valuing Surgical Science by comparing valuation metrics with similar companies.
Peers
Surgical Science Related Equities
| BICO | BICO Group | 3.57 | ||||
| HTRO | Hexatronic Group | 3.08 | ||||
| SECARE | Swedencare Publ | 1.73 | ||||
| GENO | Genovis AB | 1.07 | ||||
| MIPS | MIPS AB | 1.68 |
Additional Tools for Surgical Stock Analysis
When running Surgical Science's price analysis, check to measure Surgical Science's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Surgical Science is operating at the current time. Most of Surgical Science's value examination focuses on studying past and present price action to predict the probability of Surgical Science's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Surgical Science's price. Additionally, you may evaluate how the addition of Surgical Science to your portfolios can decrease your overall portfolio volatility.